Increased Estradiol and Improved Sleep, But Not Hot Flashes, Predict Enhanced Mood during the Menopausal Transition

Joffe, Hadine; Petrillo, Laura; Koukopoulos, Alexia E.; Viguera, Adele C.; Hirschberg, April; Nonacs, Ruta; Somley, Brittny; Pasciullo, Erica; White, David P.; Hall, Janet E.; Cohen, Lee S.

doi:10.1210/jc.2010-2503

Cited by 92 publications

(87 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, somatic symptoms made the strongest unique contribution to explaining depression scores, when controlling for the variance explained by the other predictors in the model. The finding that somatic symptoms were related to depressive symptoms independent of VMS is consistent with the work of others (Joffe et al, 2011;Mitchell & Woods, 1996). This is further evidence that the experience of VMS is unlikely to cause a reactive depression in most women.…”

Section: Discussionsupporting

confidence: 90%

Factors Associated with Depression During the Perimenopausal Transition

Gibbs

Lee

Kulkarni

2013

Women's Health Issues

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Factors Associated with Depression During the Perimenopausal Transition

Gibbs

Lee

Kulkarni

2013

Women's Health Issues

View full text Add to dashboard Cite

“…In another study, estradiol was administered to women who had depressive disorders, hot flashes and disturbed sleep in the menopause transition. Results indicated that increased estradiol levels and improved sleep quality predicted improvement in depressed mood, while reduction of hot flashes did not improve depressed mood [88]. This evidence suggested that in spite of high correlations between depressive symptoms and VMS, these variables may have distinct pathways, and hot flashes alone are not a likely cause of depression around menopause.…”

Section: Depression and Vasomotor Symptomsmentioning

confidence: 94%

“…For example, sleep problems predicted next-day negative mood, but an association with vasomotor symptoms was found only in women who had depression at the study baseline [96]. In an intervention study of women who had depressive disorders, increasing levels of estradiol and improved sleep quality predicted improvement in depressed mood in perimenopausal women, but improved hot flashes did not improve depressed mood [88]. The researchers concluded that changes in estradiol and sleep quality, rather than hot flashes, may mediate depression during the menopause transition.…”

Section: Depression and Poor Sleepmentioning

confidence: 99%

Depression in the menopause transition: risks in the changing hormone milieu as observed in the general population

Freeman

2015

womens midlife health

View full text Add to dashboard Cite

There is accumulating evidence but no definitive answers about the incidence of depressed mood in the menopause transition and its association with the changing hormonal milieu. While a changing hormonal milieu is the natural condition for all women, only a minority of mid-life women experience debilitating depressive symptoms or clinical depression. This review focuses on associations between depressed mood and the menopause transition, primarily as identified in longitudinal, population-based studies in the past decade. Further aims were to present reported associations between depressed mood and reproductive hormones in the menopause transition as evaluated in the general population and associations of depressive symptoms or clinical depression with menopausal hot flashes or poor sleep in perimenopausal women. There is evidence to support the role of the changing endocrine milieu in the development of depressed mood in the menopause transition, but the contribution of hormones as measured is small. Disentangling the numerous factors that are associated with depression in midlife women is a major challenge for research and for clinical care, where treatments are needed to improve the most distressing menopausal symptoms.

show abstract

“…The third study, a recent double-blind RCT [27] aimed at examining the role of sleep disturbance in the etiology of menopausal depression, compared the efficacy of 8 weeks of transdermal 17-β estradiol (0.05 mg/day), the hypnotic zolpidem (10 mg/day), and placebo. It included 72 peri-and postmenopausal women aged 40-60 meeting DSM-IV criteria for a unipolar depressive disorder of mild to moderate severity as well as meeting threshold criteria for an insomnia syndrome.…”

Section: The Perimenopause and Early Postmenopausementioning

confidence: 99%

Hormone Replacement Therapy in the Treatment of Perimenopausal Depression

Gordon

Girdler

2014

Curr Psychiatry Rep

View full text Add to dashboard Cite

The menopause transition is associated with a two to fourfold increased risk in major depressive disorder (MDD) and clinical elevations in depressive symptoms. While the pathophysiological mechanisms underlying this increased risk remain uncertain, ovarian hormone fluctuation is believed to play a role. To the extent that this is the case, hormone replacement therapy (HRT), through its hormone-stabilizing effects, represents a viable antidepressant treatment. The current review summarizes the most recent literature evaluating the efficacy of HRT in treating MDD in peri- and postmenopausal women. In addition, to provide a clinical context in which to interpret this research, the endocrinology and clinical phenomenology related to depression with onset in the menopause transition (D-MT) are discussed. The available evidence suggests that HRT, specifically involving estrogen delivered through a skin patch, is a promising intervention in the treatment of D-MT. However, HRT of any form is an ineffective antidepressant in women who are well into the postmenopausal period.

show abstract

Increased Estradiol and Improved Sleep, But Not Hot Flashes, Predict Enhanced Mood during the Menopausal Transition

Cited by 92 publications

References 39 publications

Factors Associated with Depression During the Perimenopausal Transition

Factors Associated with Depression During the Perimenopausal Transition

Depression in the menopause transition: risks in the changing hormone milieu as observed in the general population

Hormone Replacement Therapy in the Treatment of Perimenopausal Depression

Contact Info

Product

Resources

About